How a patient association gave rise to a company

Last updated: June 24, 2024

A patient association in rare diseases is first and foremost families who all have one thing in common: they need a cure to be found and made available.

Discover how French company AtmosR worked with a patient association to tackle the need to find a cure for Ondine:

Subscribe to our newsletter

ePRO in early phase oncology trials: A revolution on the...

Patient-Reported Outcomes in early-phase oncology clinical trialsA Stepping Stone to...

Answering the Sustainability Call: Digital Health Technologies and eCOA

Kayentis secures Silver Medal in EcoVadis sustainability evaluation with significant...

Engage patients throughout the clinical trial journey

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events